Want to see IN:BALPHARMA full AI Analyst Report?

Bal Pharma Limited (BALPHARMA) Price & Analysis

0 Followers

BALPHARMA Stock Chart & Stats

₹87.08

₹1.29(1.48%)

At close: Jul 27 4:00 PM EDT

₹87.08

₹1.29(1.48%)

Day’s Range― - ―

52-Week Range₹59.69 - ₹124.68

Previous CloseN/A

Volume164.27K

Average Volume (3M)6.72K

Market Cap

₹1.62B

Enterprise Value₹2.53K

Total Cash (Recent Filing)₹92.92M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)22.2

Beta0.58

Next Earnings

Nov 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.19%

Share Statistics

EPS (TTM)4.54

Shares Outstanding15,920,872

10 Day Avg. Volume17,760

30 Day Avg. Volume6,724

Financial Highlights & Ratios

PEG Ratio-1.14

Price to Book (P/B)1.17

Price to Sales (P/S)0.31

P/FCF Ratio-23.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Long-term Revenue GrowthThe company has delivered positive revenue growth over the measured period, indicating ongoing demand for its pharmaceutical products. Continued expansion in sales can support operating scale, broaden market reach, and provide a foundation for rebuilding earnings if profitability improves.

Diversified Pharmaceutical PortfolioBal Pharma combines finished pharmaceutical formulations with active pharmaceutical ingredients and serves both domestic and export markets. This breadth gives the business multiple product and geographic channels, which can support resilience when demand or pricing is weaker in one area.

Established Operating BaseA workforce of 939 employees and a record of positive profitability indicate an established operating platform rather than an untested business. Growing equity also provides some internal financial support, although the benefit is limited by the company’s substantial leverage.

Bears Say

High And Rising LeverageHigh and rising leverage places a persistent constraint on financial flexibility. Debt service and refinancing needs can absorb cash that might otherwise fund product development, capacity or working capital, while the balance sheet remains sensitive to weaker earnings or operating conditions.

Unreliable Free Cash FlowRepeated deeply negative free cash flow shows that accounting profitability has not consistently converted into cash. This can increase reliance on borrowing or other funding sources, reduce the company’s ability to self-finance growth, and amplify the impact of its already elevated leverage.

Thin And Inconsistent EarningsThe combination of uneven revenue growth, thin profitability and softer 2026 earnings indicates limited earnings stability. Variability in gross profit also points to changing product mix, pricing or costs, making sustained margin improvement less certain over the next several quarters.

Bal Pharma Limited News

Bal Pharma Rectifies Technical Discrepancies in NSE XBRL Filings

An announcement from Bal Pharma Limited ( ($IN:BALPHARMA) ) is now available. Bal Pharma Limited has clarified discrepancies...

2M ago

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹59.69 and its highest was ₹124.68 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.62B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Nov 14, 2026 which is in 56 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on Aug 12, 2026. The company reported ₹0.706 earnings per share for the quarter.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.19%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹0.706 in its last earnings report. Following the earnings report the stock price went up 2.457%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.